# AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF

> **NCT00396266** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 22 (actual)

## Conditions studied

- Multiple Myeloma
- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** G-CSF Plus Plerixafor

## Key facts

- **NCT ID:** NCT00396266
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2014-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00396266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00396266, "AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00396266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*